Oral N-Acetyl Cysteine Lowered IL 6 Level Among Stage V Chronic Kidney Disease Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)

Main Author: Nurhayatun, Evi; Internal Medicine Department, Medical Faculty of Sebelas Maret University Surakarta Indonesia
Format: Article info application/pdf eJournal
Bahasa: eng
Terbitan: Faculty of Medicine , 2017
Subjects:
Online Access: http://journal.uii.ac.id/index.php/JKKI/article/view/8957
http://journal.uii.ac.id/index.php/JKKI/article/view/8957/pdf-1
Daftar Isi:
  • Background. IL 6 level is increased in stage V CKD patients on CAPD. N-Acetyl Cysteine is a compound containing thiol with antioxidant and anti-inflammatory effects.Objective. To examine the effect of oral NAC on IL 6 level in stage V CKD patients on CAPD.Method. An experimental research with Randomized Double Blind Control Trial, involving 30 CKD patients on CAPD in Dr Moewardi Hospital. They were divided into control group/placebo (15 patients) and oral NAS treatment group (15 patients). IL 6 level was measured before and after 8 weeks of treatment.Result. Level of IL 6 before and after treatment in control group were (8.13 + 7.62 vs 11.16 + 8.32 , p= 0,001), significantly (p<0,001). Level of IL 6 before and after treatment in treatment group were (9.72 + 7.29 vs 6.09 + 3.82, p = 0,002); lowered significantly (p<0,05).Conclusion. Oral NAC lowered the level of IL 6 in stage V CKD patients on CAPD.